For the quarter ending 2026-03-31, RJF had $1,394M increase in cash & cash equivalents over the period. $1,054M in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenues | - | - | 1,814 | - |
| Total non-interest expenses | - | - | 263 | - |
| Pre-tax income before equity in undistributed net income of subsidiaries | - | - | 1,551 | - |
| Income tax benefit | - | - | -83 | - |
| Income before equity in undistributed net income of subsidiaries | - | - | 1,634 | - |
| Equity in undistributed net income of subsidiaries | - | - | 501 | - |
| Net income | 544 | 563 | 604 | 436 |
| Depreciation and amortization | 50 | 49 | 52 | 49 |
| Deferred income taxes, net | 77 | 35 | -48 | -50 |
| Premium and discount amortization on available-for-sale securities and bank loans and net unrealized gains/losses on other investments | 4 | -1 | 0 | 18 |
| Provisions for credit losses and legal and regulatory matters, net | 19 | 2 | 15 | 83 |
| Share-based compensation expense | 54 | 79 | 55 | 52 |
| Unrealized gains on corporate-owned life insurance policies, net of expenses | -32 | 22 | 65 | 99 |
| Other | -11 | -16 | -16 | -2 |
| Collateralized agreements, net of collateralized financings | -393 | 272 | -470 | 292 |
| Loans (provided to) financial advisors, net of repayments | 130 | 156 | 134 | 194 |
| Brokerage client receivables and other receivables, net | 685 | -206 | -64 | 30 |
| Trading instruments, net | 181 | -119 | 222 | -146 |
| Derivative instruments, net | -37 | 27 | -15 | 85 |
| Other assets | -10 | 54 | -41 | -55 |
| Brokerage client payables and other payables | 616 | 5 | -324 | 293 |
| Accrued compensation, commissions and benefits | 166 | -659 | 388 | 298 |
| Purchases and originations of loans held for sale, net of proceeds from sales of securitizations and loans held for sale | -90 | -105 | 131 | 57 |
| Net cash provided by operating activities | 1,099 | -10 | 796 | 691 |
| Increase in bank loans, net | 1,435 | 2,137 | 1,667 | 1,710 |
| Proceeds from sales of loans held for investment | 35 | 81 | 27 | 135 |
| Purchases of available-for-sale securities | 343 | 66 | 102 | 180 |
| Available-for-sale securities maturations, repayments and redemptions | 575 | 360 | 445 | 522 |
| Proceeds from sales of available-for-sale securities | 0 | 0 | 0 | 0 |
| Cash paid for acquisition, net of cash acquired | 92 | - | - | - |
| Additions to property and equipment | 45 | 46 | 44 | 57 |
| Sales/(purchases) of federal reserve bank (frb) and federal home loan bank (fhlb) stock, net | - | - | -3 | 1 |
| Renewable energy tax credit equity investments | - | - | 20 | 0 |
| Sales/(purchases) of other investments, net | - | - | 73 | - |
| Sales of federal reserve bank (frb) and federal home loan bank (fhlb) stock | 0 | - | - | - |
| Other investing activities, net | 32 | 57 | -8 | 11 |
| Net cash used in investing activities | -1,337 | -1,865 | -1,423 | -1,302 |
| Increase in bank deposits | 2,271 | 1,255 | 1,648 | 846 |
| Repurchases of common stock and share-based awards withheld for payment of withholding tax requirements | 405 | 513 | 353 | 455 |
| Dividends on common and preferred stock | 109 | 112 | 102 | 103 |
| Employee stock purchases and exercise of stock options | 14 | 9 | 5 | 7 |
| Redemption of preferred stock | 81 | - | 0 | - |
| Proceeds from senior notes issuance, net of debt issuance costs paid | - | - | 1,480 | - |
| Redemption of subordinated notes | - | - | 98 | - |
| Proceeds from federal home loan bank (fhlb) advances | 50 | 250 | 0 | 750 |
| Repayments of fhlb advances | 50 | 250 | 50 | 1,650 |
| Other financing, net | 0 | -10 | 2 | -3 |
| Net cash provided by/(used in) financing activities | 1,690 | 629 | 2,532 | 292 |
| Effect of exchange rate changes on cash and cash equivalents, including those segregated for regulatory purposes | -58 | 29 | -83 | 48 |
| Net increase/(decrease) in cash and cash equivalents, including those segregated for regulatory purposes and restricted cash | 1,394 | -1,217 | 1,822 | -122 |
| Cash and cash equivalents, including those segregated for regulatory purposes and restricted cash at beginning of year | 13,570 | 14,787 | 12,965 | 13,087 |
| Cash and cash equivalents, including those segregated for regulatory purposes and restricted cash at end of period | 14,964 | 13,570 | 14,787 | 12,965 |